Xencor Stock

Xencor Equity

The The Equity of Xencor (XNCR) as of Aug 9, 2026 is 635.59 M USD. In the previous year, The Equity was 677.61 M USD — a change of -6.20% (lower).

Equity

635.59 MUSD

YoY

-6.20%

Last updated:

In 2026, Xencor's equity was 635.59 M USD, a -6.20% increase from the 677.61 M USD equity in the previous year.

Access this data via the Eulerpool API

Xencor Stock analysis

What does Xencor do? The company Xencor Inc was founded in 1997 and has since become a significant biotechnology company specializing in the development of therapeutic proteins. Xencor's goal is to develop innovative and tailored therapies for the treatment of serious diseases such as cancer and autoimmune diseases. The company is headquartered in Monrovia, California, and employs a growing number of scientists, engineers, and other professionals specialized in the development of new themes and products. Xencor has acquired a variety of patents over the years to protect its intellectual property. Its business model is based on the development of new therapeutics through its proprietary XmAb technology platform, which enables the production of highly specific polyclonal antibodies that can improve the efficiency and safety of disease treatments. Xencor has divided its business activities into various divisions, including the development of immuno-oncology products, autoimmune therapies, and new methods for the therapy of inflammatory bowel diseases. The company has developed a wide range of products, including a new class of therapeutic antibodies that mobilize and strengthen patients' own immune system to fight cancer cells. By combining these antibodies with other therapies, the effectiveness of the treatment can be further increased. In the autoimmune diseases division, Xencor has developed new therapeutics to better regulate patients' immune system and treat dangerous autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, or lupus. Another focus of the company is the development of therapies for inflammatory bowel diseases such as ulcerative colitis or Crohn's disease. By developing specific antibodies involved in the inflammatory processes in the intestine, Xencor can contribute to improving the treatment of these conditions. Xencor aims to accelerate the development of new therapeutics while improving their efficacy and safety. With the help of its proprietary XmAb technology platform, the company is able to develop new drugs faster and more effectively than conventional methods. Through the combination of technology, research and development, and a high level of commitment, Xencor pursues its vision and has successfully established itself as one of the leading companies in the biotechnology industry. Xencor is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Xencor's Equity

Xencor's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Xencor's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Xencor's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Xencor's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Xencor’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Xencor stock

The Equity of Xencor is 635.59 M USD in 2026.

The Equity of Xencor changed from 677.61 M USD to 635.59 M USD, representing a -6.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Xencor since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Xencor historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Xencor

All Key Metrics — Xencor